The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s 3D bioprinting market report forecasts the 3D bioprinting market size to grow to $3.14 Billion by 2027, with a CAGR (compound annual growth rate) of more than 19%.

Learn More On The 3D Bioprinting Market Report 2023 – https://www.thebusinessresearchcompany.com/report/3d-bioprinting-global-market-report

3D Bioprinting Market Size Forecast
The global 3D bioprinting market is expected to grow from $1.32 billion in 2022 to $1.54 billion in 2023 at a compound annual growth rate (CAGR) of 16.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The 3D bioprinting market size is expected to grow to $3.14 billion in 2027 at a CAGR of 19.5%.

North America held the largest 3D bioprinting market share, and Asia-Pacific was the fastest-growing region in 2022.

Key 3D Bioprinting Market Driver ­– Rise In Governments And Private Funding To Support 3D Bioprinting Research Activities
For instance, in May 2021, Readily3d SA, a Switzerland-based bioprinting company, received funding of $600,000 from the European Union to develop a living miniature model of the pancreas using its Tomolite 3D bioprinting technique. The Australian Minister for Health funded Curtin University with $737,690 in June 2020 to develop and optimize 3D technology for bioprinting skin tissue directly onto model wounds as a prelude to human skin restoration.

Request for A Sample Of The Global 3D Bioprinting Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5341&type=smp

Key 3D Bioprinting Market Trend – Adopting Artificial Intelligence
Artificial intelligence (AI) is increasingly being used in 3D bioprinting to fabricate biotissues in a layer-to-layer fashion from a digital 3D model using a combination of cells, growth factors, and biomaterials. Artificial intelligence is a branch of technology that deals with the simulation of human behavior in machines. AI is used in bioprinting to give suggestions on the best possible printing parameters needed to produce a biocompatible tissue that can fit the patient’s physiological makeup, by analyzing data and identifying patterns throughout the bioprinting process. For instance, in June 2021, researchers at Queensland University of Technology’s (QUT) Center in Transformative Biomimetics in Bioengineering, and Oregon University, integrated AI and machine vision into 3D printers to manufacture customized medical implants. In addition to this, in September 2020, Researchers at Rice University used AI to speed up the development of 3D printed bioscaffolds that help injuries heal.

3D Bioprinting Market Segment
1) By Component: 3D Bioprinters, Bioinks
2) By Material: Living Cells, Hydrogels, Extracellular Matrices, Other Materials
3) By Application: Research Applications, Clinical Application, Other Applications
4) By End User: Research Organization And Academic Institutes, Biopharmaceuticals Companies, Hospitals, Other End Users

3D Bioprinting Market Major Players and Strategies
Major players in the 3D bioprinting market are Organovo Holdings Inc., Allevi Inc., Cellink, Aspect Biosystems Ltd., 3D Systems Corporation, Cyfuse Biomedical KK, Envisiontec Inc., Poietis, TeVido BioDevices, Nano3D Biosciences Inc., Digilab Inc., RegenHU, GeSIM GmbH, Advanced Solutions Life Sciences LLC, Regenovo Biotechnology Co. Ltd., Regemat 3D S.L., Bio3D Technologies, Stratasys Ltd., ROKIT Healthcare, Inventia Life Science PTY Ltd., Vivax Bio LLC, GE Healthcare, and 3D Biotek.

In May 2021, 3D Systems, a US-based company engaged in offering 3D bioprinting technology, announced the acquisition of Allevi Inc. for an undisclosed amount. Through this acquisition, 3D Systems plans to utilize Allevi’s expertise to develop applications in the future for the development of human organs in the long term and become a market leader in bioprinting. Allevi Inc. is a US-based company that manufactures 3D bioprinters and bio-inks which are used by researchers.

The 3D Bioprinting Global Market Report 2023 covers regional data on 3D bioprinting market size, 3D bioprinting market trends and drivers, opportunities, strategies, and 3D bioprinting market competitor analysis. The countries covered in the 3D bioprinting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

3D Bioprinting is a type of additive manufacturing that prints live structures layer by layer, mimicking the behavior of actual living systems, using cells and other biocompatible materials like inks, also known as bio-inks. 3D bioprinting materials are mainly used in connection with drug research and most recently as cell scaffolds to help repair damaged ligaments and joints.

View More Reports Related To The 3D Bioprinting Market –
3D Cell Culture Technologies Global Market Report 2023
3D Printed Implants Global Market Report 2023
3D Printed Medical Devices Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: